Paper Details 
Original Abstract of the Article :
Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Recently, the eradication rate of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection has decreased to less than 80% worldwide with the use of clarithromycin-based triple therapy owing to the increased resistance of <i>H. pylori</i> to antibiotics,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.4166/kjg.2017.70.4.176

データ提供:米国国立医学図書館(NLM)

High-Dose Dual Therapy for Helicobacter pylori Infections: A New Oasis in the Desert of Resistance

The desert of Helicobacter pylori (H. pylori) infection is vast and unforgiving, with increasing antibiotic resistance posing a significant challenge. This study explores a new strategy for combating this resilient bacterium, focusing on a high and frequent dose dual therapy of dexlansoprazole and amoxicillin. The authors sought to determine the eradication rate of H. pylori using this approach in a region with high clarithromycin resistance.

The study, a single-arm prospective study, demonstrated promising results, revealing a high eradication rate of H. pylori using the high-dose dual therapy. This finding suggests that this approach may offer a viable alternative to traditional triple therapies, particularly in regions where clarithromycin resistance is prevalent.

A Potential Solution to Antibiotic Resistance

This study offers a glimmer of hope in the battle against H. pylori infection, particularly in the face of rising antibiotic resistance. The high eradication rate achieved with the high-dose dual therapy suggests that this approach could be a valuable tool in combating this persistent infection.

Navigating the Desert of H. pylori Infection

This research sheds light on a new strategy for tackling H. pylori infection, offering a potential solution to the growing problem of antibiotic resistance. By exploring innovative approaches like high-dose dual therapy, researchers can continue to develop new weapons in the fight against this resilient bacterium.

Dr.Camel's Conclusion

This study highlights the potential of a high and frequent dose dual therapy of dexlansoprazole and amoxicillin for eradicating H. pylori infection, particularly in regions with high clarithromycin resistance. The promising results offer hope for a new weapon in the fight against this persistent bacterium, offering a potential solution to the growing challenge of antibiotic resistance.

Date :
  1. Date Completed 2018-06-11
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

29060955

DOI: Digital Object Identifier

10.4166/kjg.2017.70.4.176

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.